ArticleEuropean journal of nuclear medicine and molecular imaging2026
Safety and efficacy of [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tolerability of [European journal of nuclear medicine and molecular imaging · 2026Article
- Comparative safety profiles of enzalutamide, olaparib, and lutetium Lu-177 vipivotide tetraxetan in patients with prostate cancer: a real-world disproportionality analysis of the FAERS database.World journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (RPT) is a safe and well-tolerated treatment option for metastatic, castration-resistant prostate cancer (mCRPC). A new radioligand, comprising ibuprofen as an albumin-binding entity, [
methodsFrom July 2021 to January 2023 a total of seventeen eligible patients, sixteen (median age 71 years, range 63-83) were selected to receive up to four cycles of [
resultsSeven participants received 4 cycles of [
conclusionOverall survival and response rates of patients are consistent with previous reports on PSMA-targeted RPT while the absence of xerostomia can be considered an improvement. Up to four cycles of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.